Louisiana State Employees Retirement System Invests $3.62 Million in Roivant Sciences Ltd. $ROIV

Posted by Stanley Muller on Jun 28th, 2026

Louisiana State Employees Retirement System bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 130,700 shares of the company’s stock, valued at approximately $3,620,000.

Several other hedge funds have also recently added to or reduced their stakes in ROIV. Fifth Third Wealth Advisors LLC boosted its holdings in Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after purchasing an additional 445 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after buying an additional 516 shares during the period. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Finally, Fifth Third Bancorp boosted its stake in Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after buying an additional 588 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV opened at $34.07 on Friday. The company has a market cap of $24.51 billion, a price-to-earnings ratio of -56.78 and a beta of 1.13. The stock has a fifty day moving average price of $29.66 and a two-hundred day moving average price of $26.77. Roivant Sciences Ltd. has a 52-week low of $10.70 and a 52-week high of $34.68.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. During the same quarter in the prior year, the business earned ($0.29) earnings per share. As a group, research analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Insider Buying and Selling

In other Roivant Sciences news, CAO Jennifer Humes sold 13,538 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total transaction of $384,073.06. Following the sale, the chief accounting officer owned 84,191 shares of the company’s stock, valued at $2,388,498.67. This represents a 13.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. The trade was a 11.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 903,312 shares of company stock worth $27,437,883 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of several recent analyst reports. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, TD Cowen lifted their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Check Out Our Latest Stock Report on Roivant Sciences

Roivant Sciences Profile

(Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.